Healius Limited (ASX:HLS)

Market Cap	562.75M
Revenue (ttm)	1.34B
Net Income (ttm)	-151.20M
Shares Out	726.13M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	50.36
Dividend	0.41 (53.29%)
Ex-Dividend Date	May 9, 2025

Volume	987,220
Average Volume	8,140,824
Open	0.7900
Previous Close	0.7950
Day's Range	0.7700 - 0.7950
52-Week Range	0.6620 - 1.8600
Beta	0.41
RSI	42.05
Earnings Date	Aug 21, 2025

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 9,658
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In 2025, Healius's revenue was 1.34 billion, a decrease of -23.02% compared to the previous year's 1.75 billion. Losses were -151.20 million, -76.59% less than in 2024.